208 related articles for article (PubMed ID: 34123384)
1. Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia-a case report.
Sasaki K; Yokota Y; Isojima T; Fujii M; Hasui K; Chen Y; Saito K; Takahata T; Kindaichi S; Sato A
Respirol Case Rep; 2021 Jul; 9(7):e00796. PubMed ID: 34123384
[TBL] [Abstract][Full Text] [Related]
2. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract][Full Text] [Related]
3. Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase‑positive non‑small cell lung cancer: A case report.
Wang H; Wu Z; Shi G; Zhou J; Xiao Z
Oncol Lett; 2023 Dec; 26(6):526. PubMed ID: 38020308
[TBL] [Abstract][Full Text] [Related]
4. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract][Full Text] [Related]
5. ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report.
Yamamoto K; Toyokawa G; Kozuma Y; Shoji F; Yamazaki K; Takeo S
Thorac Cancer; 2021 Jun; 12(11):1761-1764. PubMed ID: 33939293
[TBL] [Abstract][Full Text] [Related]
6. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
7. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
8. Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report.
Makimoto G; Kawakado K; Nakanishi M; Tamura T; Kuyama S
Case Rep Oncol; 2021; 14(1):197-201. PubMed ID: 33776703
[TBL] [Abstract][Full Text] [Related]
9. Safety of lorlatinib following alectinib-induced pneumonitis in two patients with
Myall NJ; Lei AQ; Wakelee HA
Transl Lung Cancer Res; 2021 Jan; 10(1):487-495. PubMed ID: 33569330
[TBL] [Abstract][Full Text] [Related]
10. Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis.
Ando K; Manabe R; Kishino Y; Kusumoto S; Yamaoka T; Tanaka A; Ohmori T; Sagara H
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359604
[TBL] [Abstract][Full Text] [Related]
11. Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.
Goto Y; Shukuya T; Murata A; Kikkawa H; Emir B; Wiltshire R; Miura S
Cancer Sci; 2023 Jun; 114(6):2560-2568. PubMed ID: 36866958
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
[TBL] [Abstract][Full Text] [Related]
13. Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases.
Murakami Y; Kawashima Y; Chiba S; Hara S; Yamazaki Y; Doman T; Saito S; Odaka T; Ogasawara T; Shimizu H; Sugisaka J; Aiba T; Toi Y; Yamanda S; Kimura Y; Sugawara S
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1981. PubMed ID: 38212894
[TBL] [Abstract][Full Text] [Related]
14. A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With
Goto Y; Kenmotsu H; Tamiya M; Murakami S; Kurata T; Yanagitani N; Taniguchi H; Kuyama S; Shimizu J; Yokoyama T; Shimada N; Maeda T; Tamiya A; Uchiyama A; Imaizumi K; Takahama T; Kato T; Hayashi H; Shiraiwa N; Toyoizumi S; Kikkawa H; Thomaidou D; Nishio M
JTO Clin Res Rep; 2023 May; 4(5):100508. PubMed ID: 37250506
[TBL] [Abstract][Full Text] [Related]
15. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
16. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
[TBL] [Abstract][Full Text] [Related]
17. Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in
Zhu VW; Nagasaka M; Kubota T; Raval K; Robinette N; Armas O; Al-Holou W; Ou SI
Lung Cancer (Auckl); 2020; 11():13-18. PubMed ID: 32021525
[TBL] [Abstract][Full Text] [Related]
18. Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.
Karachaliou N; Fernandez Bruno M; Bracht JWP; Rosell R
Onco Targets Ther; 2019; 12():4567-4575. PubMed ID: 31354290
[TBL] [Abstract][Full Text] [Related]
19. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
[TBL] [Abstract][Full Text] [Related]
20. Successful salvage surgery followed by second ALK-TKI after alectinib failure in a patient with ALK-positive NSCLC.
Hashimoto H; Komori K; Kameda K; Taguchi S; Ozeki Y
Surg Case Rep; 2022 Apr; 8(1):59. PubMed ID: 35366157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
